Recursion therapeutics stock
WebApr 12, 2024 · Recursion Pharmaceuticals (NASDAQ:RXRX) has filed to raise $306 million in an IPO of its Class A common stock, according to an S-1 registration statement. The firm is developing treatments for ... WebWe would like to show you a description here but the site won’t allow us.
Recursion therapeutics stock
Did you know?
WebApr 10, 2024 · SVB Securities analyst Mani Foroohar reiterated a Hold rating on Recursion Pharmaceuticals (RXRX - Research Report) on February 27 and set a price target of $9.00. … WebJul 13, 2024 · SALT LAKE CITY, July 13, 2024 - Recursion (NASDAQ: RXRX), a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, machine learning and engineering, today announced its formation of a Therapeutics Advisory Board (TAB), chaired by Joseph Miletich, MD, PhD. …
WebRecursion Pharmaceuticals is an automated drug discovery platform. The company combines experimental biology, automation, and artificial intelligence in a parallel system … WebRecursion Pharmaceuticals Overview Update this profile Founded 2013 Status Public Employees 500 Stock Symbol RXRX Investments 2 Share Price $6.65 (As of Thursday …
WebWe operate at the intersection and cutting-edge of science and technology. Unlike traditional biotechnology companies, our rapidly growing team of more than 200 Recursionauts is … WebApr 27, 2024 · Recursion Pharmaceuticals Inc. uses machine learning to hunt for new therapies. ... REC-259618,and REC-648647) with the potential to be orally bioavailable, CNS-penetrant, disease modifying therapeutics for multiple subtypes of Batten disease. ... investors are advised that past stock performance is not indicative of future price action.
WebJun 30, 2024 · Therapeutics Advisory Board: A Therapeutics Advisory Board is being formed to advise Recursion's executive team and Board of Directors regarding key research and development issues. The Therapeutics Advisory Board is chaired by Joseph Miletich , MD, PhD, who previously was Merck Research Laboratories' Senior Vice President of Research …
WebNews Recursion Pharmaceuticals Inc. Significant News Only No significant news for RXRX in the past two years. Key Stock Data P/E Ratio (TTM) N/A EPS (TTM) $-1.44 Market Cap … california fan palm vector black and whitecalifornia famous people in historyWebApr 10, 2024 · Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations … california fantasy 5 most overdue numbersWebApr 14, 2024 · Esperion Therapeutics Inc (ESPR) stock is trading at $1.21 as of 11:29 AM on Friday, Apr 14, a drop of -$0.14, or -10.37% from the previous closing price of $1.35. The stock has traded between $1.21 and $1.35 so far today. Volume today is light. So far 949,750 shares have traded compared to average volume of 6,452,500 shares. california farm and gardenWebFind the latest Tango Therapeutics, Inc. (TNGX) stock quote, history, news and other vital information to help you with your stock trading and investing. coa hub tai chi maureen isevitchWebApr 5, 2024 · The latest price target for Recursion Pharmaceuticals ( NASDAQ: RXRX) was reported by Needham on Thursday, March 16, 2024. The analyst firm set a price target for 17.00 expecting RXRX to rise to ... california family missing found deadWebApr 11, 2024 · According to analysts, Recursion Pharmaceuticals's stock has a predicted upside of 36.20% based on their 12-month price targets. What analysts cover Recursion Pharmaceuticals? Recursion Pharmaceuticals has been rated by Needham & Company LLC, and SVB Leerink in the past 90 days. Stock Ratings Reports and Tools Apple Meta … coa housing